DE60031792D1 - Schimärische amyloid-beta peptide - Google Patents
Schimärische amyloid-beta peptideInfo
- Publication number
- DE60031792D1 DE60031792D1 DE60031792T DE60031792T DE60031792D1 DE 60031792 D1 DE60031792 D1 DE 60031792D1 DE 60031792 T DE60031792 T DE 60031792T DE 60031792 T DE60031792 T DE 60031792T DE 60031792 D1 DE60031792 D1 DE 60031792D1
- Authority
- DE
- Germany
- Prior art keywords
- chimeric
- cleavage product
- precursor
- mature protein
- peptide cleavage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title 1
- 108091006116 chimeric peptides Proteins 0.000 abstract 4
- 230000007030 peptide scission Effects 0.000 abstract 4
- 239000002243 precursor Substances 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 230000003053 immunization Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 210000002443 helper t lymphocyte Anatomy 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16968799P | 1999-12-08 | 1999-12-08 | |
US169687P | 1999-12-08 | ||
PCT/US2000/033203 WO2001042306A2 (en) | 1999-12-08 | 2000-12-08 | Chimeric peptides (short b-cell epitope joined to a t-cell epitope) and their use for immunization |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60031792D1 true DE60031792D1 (de) | 2006-12-21 |
DE60031792T2 DE60031792T2 (de) | 2007-02-22 |
Family
ID=22616757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60031792T Expired - Lifetime DE60031792T2 (de) | 1999-12-08 | 2000-12-08 | Schimärische amyloid-beta peptide |
Country Status (15)
Country | Link |
---|---|
US (2) | US7901689B2 (de) |
EP (1) | EP1237930B1 (de) |
JP (1) | JP4804690B2 (de) |
CN (2) | CN1414976A (de) |
AT (1) | ATE344803T1 (de) |
AU (1) | AU784925B2 (de) |
CA (1) | CA2393763A1 (de) |
CY (1) | CY1108538T1 (de) |
DE (1) | DE60031792T2 (de) |
DK (1) | DK1237930T3 (de) |
ES (1) | ES2275570T3 (de) |
IL (2) | IL149976A0 (de) |
PT (1) | PT1237930E (de) |
WO (1) | WO2001042306A2 (de) |
ZA (1) | ZA200205032B (de) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6913745B1 (en) * | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
NO314086B1 (no) * | 1998-05-08 | 2003-01-27 | Gemvax As | Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til |
US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
CA2393763A1 (en) * | 1999-12-08 | 2001-06-14 | Mindset Biopharmaceuticals (Usa), Inc. | Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies |
AU783144B2 (en) | 2000-02-21 | 2005-09-29 | H. Lundbeck A/S | Novel method for down-regulation of amyloid |
BR0108566A (pt) * | 2000-02-21 | 2002-11-19 | Pharmexa As | Método para a regulação negativa in vivo de proteìna amilóide em um animal, incluindo um ser humano e para o tratamento e/ou prevenção e/ou melhora da doença de alzheimer ou outras doenças e condições cartacterizadas por depósitos de amilóide, análogo de um polipeptìdeo amiloidogênico,composição imunogênica, fragmento de ácido nucleico, vetor, célula transformada, composição para induzir a produção de anticorpos contra um polipeptìdeo amiloidogênico, linhagem celular estável, métodos para a preparação de uma célula, para a identificação de um polipeptìdeo amiloidogênico modificado, e para preparação de uma composição imunogênica, uso de um polipeptìdeo amiloidogênico ou de uma subsequência do mesmo, e, uso de um análogo de um polipeptìdeo amiloidogênico |
TW200628612A (en) * | 2000-07-19 | 2006-08-16 | Pharmacia & Up John Company | Substrates and assays for β-secretase activity |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
US7196163B2 (en) | 2001-05-22 | 2007-03-27 | Merk & Co., Inc. | Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity |
US6906169B2 (en) * | 2001-05-25 | 2005-06-14 | United Biomedical, Inc. | Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide |
MY144532A (en) * | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
CA2466841A1 (en) * | 2001-11-21 | 2003-06-05 | New York University | Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid .beta., prion protein, amylin, .alpha.-synuclein, or polyglutamine repeats for induction of an immune response thereto |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
EP1545582A4 (de) * | 2002-10-01 | 2008-09-17 | Univ Northwestern | Von amyolid-beta abgeleitete diffundierbare liganden (addls), addl-ersatzstoffe, addl-bindungsmoleküle und verwendungen davon |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
PE20050627A1 (es) | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
JP2008523815A (ja) | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミテッド | 認知の改善における使用のためのヒト化アミロイドβ抗体 |
PL1954718T3 (pl) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał |
KR101667623B1 (ko) | 2005-11-30 | 2016-10-19 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
DE102006015001A1 (de) * | 2006-03-31 | 2007-10-11 | NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen | Verfahren zum Nachweis und/oder zur Anreicherung von Analytproteinen und/oder Analytpeptiden aus einer komplexen Proteinmischung |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
CA2653628C (en) | 2006-06-01 | 2015-07-14 | Elan Pharmaceuticals, Inc. | Neuroactive fragments of app |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
EP1944314A1 (de) * | 2007-01-11 | 2008-07-16 | Philipps-Universität Marburg | Diagnose von Morbus Alzheimer und anderen Demenzerkrankungen |
JP2010515717A (ja) | 2007-01-11 | 2010-05-13 | フィリップス−ウニベルジテート・マールブルク | アルツハイマーおよび他の神経性認知症疾患の診断ならびに処置 |
EP2124952A2 (de) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Verfahren zur behandlung von amyloidosen |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
DK2182983T3 (da) | 2007-07-27 | 2014-07-14 | Janssen Alzheimer Immunotherap | Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer |
EA026787B1 (ru) * | 2007-08-27 | 2017-05-31 | Общество С Ограниченной Ответственностью "Ниармедик Плюс" | Конструкция нуклеиновой кислоты и ее применение для лечения, предотвращения и сдерживания болезни альцгеймера |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
GB0812586D0 (en) * | 2008-07-09 | 2008-08-13 | Ucl Business Plc | Chimaeric peptide |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
JP2013521233A (ja) | 2010-02-25 | 2013-06-10 | ヤンセン アルツハイマー イミュノセラピー | Aβを標的とする免疫療法のPETモニタリング |
MX336196B (es) | 2010-04-15 | 2016-01-11 | Abbvie Inc | Proteinas de union a amiloide beta. |
MX358739B (es) | 2010-08-14 | 2018-09-03 | Abbvie Inc Star | Proteinas de union a amiloide beta. |
US8703137B2 (en) | 2011-01-31 | 2014-04-22 | Intellect Neurosciences Inc. | Treatment of tauopathies |
KR102020072B1 (ko) * | 2011-03-16 | 2019-11-04 | 프로비오드룩 아게 | 진단 항체 시험 |
EP2887955B1 (de) * | 2012-08-21 | 2020-08-19 | Institute for Molecular Medicine, Inc. | Zusammensetzungen und verfahren mit erkrankungen im zusammenhang mit ablagerungen von amyloid, tau und alpha-synuklein |
US9102752B2 (en) | 2013-03-15 | 2015-08-11 | United Biomedical, Inc. | Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type |
JP7204653B2 (ja) * | 2017-08-30 | 2023-01-16 | Kmバイオロジクス株式会社 | 改変型HSV gDタンパク質及びこれを含むワクチン |
CN112512552A (zh) * | 2018-07-12 | 2021-03-16 | 海克斯麦治疗公司 | 自组装肽支架 |
EP3946605A1 (de) | 2019-04-05 | 2022-02-09 | Tauc3 Biologics Limited | Anti-tauc3-antikörper und verwendungen davon |
WO2022235678A1 (en) * | 2021-05-03 | 2022-11-10 | Ohio State Innovation Foundation | Human anti-coronavirus peptide vaccines and methods of their use |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6018021A (en) * | 1994-10-19 | 2000-01-25 | The Research Foundation Of State University Of New York | Human transaldolase: an autoantigen with a function in metabolism |
AUPO390396A0 (en) * | 1996-11-29 | 1996-12-19 | Csl Limited | Novel promiscuous T helper cell epitopes |
EP2305709A1 (de) * | 1997-04-09 | 2011-04-06 | Intellect Neurosciences, Inc. | Beta-Amyloid-Enden-spezifische rekombinante Antikörper, DNS-Codierung und Verwendungsverfahren |
US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
CA2393763A1 (en) * | 1999-12-08 | 2001-06-14 | Mindset Biopharmaceuticals (Usa), Inc. | Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies |
-
2000
- 2000-12-08 CA CA002393763A patent/CA2393763A1/en not_active Abandoned
- 2000-12-08 JP JP2001543601A patent/JP4804690B2/ja not_active Expired - Fee Related
- 2000-12-08 EP EP00990195A patent/EP1237930B1/de not_active Expired - Lifetime
- 2000-12-08 CN CN00818137A patent/CN1414976A/zh active Pending
- 2000-12-08 AT AT00990195T patent/ATE344803T1/de active
- 2000-12-08 AU AU27256/01A patent/AU784925B2/en not_active Ceased
- 2000-12-08 PT PT00990195T patent/PT1237930E/pt unknown
- 2000-12-08 IL IL14997600A patent/IL149976A0/xx unknown
- 2000-12-08 DE DE60031792T patent/DE60031792T2/de not_active Expired - Lifetime
- 2000-12-08 US US09/731,899 patent/US7901689B2/en not_active Expired - Fee Related
- 2000-12-08 CN CN2010101066741A patent/CN101935352A/zh active Pending
- 2000-12-08 DK DK00990195T patent/DK1237930T3/da active
- 2000-12-08 WO PCT/US2000/033203 patent/WO2001042306A2/en active IP Right Grant
- 2000-12-08 ES ES00990195T patent/ES2275570T3/es not_active Expired - Lifetime
-
2002
- 2002-06-02 IL IL149976A patent/IL149976A/en not_active IP Right Cessation
- 2002-06-21 ZA ZA200205032A patent/ZA200205032B/en unknown
-
2007
- 2007-01-29 CY CY20071100123T patent/CY1108538T1/el unknown
-
2010
- 2010-11-22 US US12/951,836 patent/US20110280879A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ATE344803T1 (de) | 2006-11-15 |
DK1237930T3 (da) | 2007-03-19 |
CN101935352A (zh) | 2011-01-05 |
US20110280879A1 (en) | 2011-11-17 |
WO2001042306A3 (en) | 2001-11-01 |
EP1237930A2 (de) | 2002-09-11 |
US20060088548A1 (en) | 2006-04-27 |
AU2725601A (en) | 2001-06-18 |
DE60031792T2 (de) | 2007-02-22 |
PT1237930E (pt) | 2007-02-28 |
ZA200205032B (en) | 2003-09-22 |
AU784925B2 (en) | 2006-07-27 |
JP4804690B2 (ja) | 2011-11-02 |
EP1237930B1 (de) | 2006-11-08 |
JP2003516419A (ja) | 2003-05-13 |
ES2275570T3 (es) | 2007-06-16 |
US7901689B2 (en) | 2011-03-08 |
CA2393763A1 (en) | 2001-06-14 |
WO2001042306A2 (en) | 2001-06-14 |
CN1414976A (zh) | 2003-04-30 |
CY1108538T1 (el) | 2014-04-09 |
IL149976A (en) | 2012-10-31 |
IL149976A0 (en) | 2002-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60031792D1 (de) | Schimärische amyloid-beta peptide | |
KR100767146B1 (ko) | Aβ 펩티드를 격리시키는 인간화 항체 | |
US10400018B2 (en) | Tau peptides, anti-tau antibodies, and methods of use thereof | |
EP1959991B1 (de) | Therapeutischer impfstoff | |
ES2541134T3 (es) | Anticuerpos de MASP-2 | |
NO20131483L (no) | Immunologiske fremgangsmåter og preparater for behandling av Alzheimers sykdom | |
UA90846C2 (ru) | ГУМАНИЗИРОВАННОЕ АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С БЕТА-АМИЛОИДНЫМ ПЕПТИДОМ (Ab) | |
KR101792887B1 (ko) | 아넥신-i(리포코르틴 1)을 조절하여 자가 면역 질환의 치료 | |
EP3072522A1 (de) | Behandlungen und verfahren mit anti-kir-kombination | |
KR20050086529A (ko) | 아세틸화 단백질 | |
BR112013028429B1 (pt) | Anticorpo monoclonal humano, molécula de ácido nucleico, cassete de expressão, célula de um microrganismo transgênico, método para gerar um anticorpo isolado, composição, uso de um anticorpo, e, artigo de fabricação | |
PE20110802A1 (es) | Un anticuerpo antagonista de pcsk9 | |
MX2020011391A (es) | Anticuerpo bcma humanizado y linfocitos t car-bcma. | |
RU2013110876A (ru) | Активируемые биспецифические антитела | |
AR062065A1 (es) | Anticuerpo humanizado | |
US9315555B2 (en) | Clostridium difficile antigens | |
DK1090039T3 (da) | Peptidsammensætning som immunogen til behandling af allergi | |
MX2007013626A (es) | Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos. | |
PE20050712A1 (es) | Anticuerpos rg1 | |
BR112022001923A2 (pt) | Proteína de ligação ao antígeno, ácido nucleico isolado, célula hospedeira recombinante, composição farmacêutica, método de produção da proteína de ligação ao antígeno | |
BR112020021111A2 (pt) | anticorpo multiespecífico, ácido nucleico e formulação farmacêutica | |
US9879076B2 (en) | Methods and compositions with immune therapy for treatment of dementia | |
MX2021010404A (es) | Anticuerpos que se unen a una forma escindida de calreticulina mutante, y agente de diagnostico, preventivo o terapeutico para las neoplasias mieloproliferativas. | |
KR20200116143A (ko) | 혈액-뇌 장벽을 관통이동하는 화합물 및 이의 용도 | |
ES2201929B1 (es) | Anticuerpos policlonales, metodo de preparacion y uso de los mismos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8381 | Inventor (new situation) |
Inventor name: CHAIN, BENJAMIN, LONDON NW11 8AJ, GB |
|
8364 | No opposition during term of opposition |